Velocity Clinical Research, San Bernardino
Velocity Clinical Research, San Bernardino
San Bernardino, California, United States7 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN) | Diabetic Peripheral Neuropathic Pain | Active, not recruiting | Phase 3 | 2026-10-09 | NCT06696443 | |
| Randomized Study in Children and Adolescents With Migraine: Acute Treatment | Ear Diseases, Nausea, Neurologic Manifestations, Pathological Conditions, Signs and Symptoms, Photophobia, Sensation Disorders, Signs and Symptoms, Signs and Symptoms, Digestive, brain disorder, central nervous system disorder, eye disorder, headache disorder, hearing disorder, hyperacusis, hypnic headache, migraine disorder, nervous system disorder, otorhinolaryngologic disease, vision disorder | Recruiting | Phase 3 | 2026-09-24 | NCT04649242 | |
| A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older | Clostridoides Difficile Associated Disease | Recruiting | Phase 3 | 2026-09-09 | NCT07282665 | |
| A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults | Infections, RNA Virus Infections, avian influenza, bird disease, influenza, non-human animal disease, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease | Active, not recruiting | Phase 3 | 2026-08-11 | NCT07496450 | |
| Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy | Diabetic Peripheral Neuropathic Pain | Recruiting | Phase 3 | 2026-06-15 | NCT06628908 | |
| A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age | COVID-19, Coronaviridae Infections, Infections, Nidovirales infectious disease, Orthocoronavirinae infectious disease, RNA Virus Infections, lung disorder, pneumonia, respiratory system disorder, respiratory tract infectious disorder, viral infectious disease, viral pneumonia | Active, not recruiting | Phase 3 | 2026-04-13 | NCT07300839 | |
| Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) | Body Weight, Nutritional and Metabolic Diseases, Overweight, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, nutritional disorder, obesity disorder, overnutrition | Active, not recruiting | Phase 4 | 2026-03-31 | NCT06098079 |